Form 4: Bioventus Director Martin Sutter Reports RSU Transactions

Director Martin Sutter acquired 32,282 shares of Bioventus Class A Common Stock via RSU vesting and was granted 25,146 new RSUs.

Summary

• Director Martin P. Sutter exercised 32,282 Restricted Stock Units (RSUs) on June 2, 2026, converting them into Class A Common Stock at no cost.
• Following the transaction, Sutter holds 117,523 shares directly and maintains an indirect interest in 13,021,324 shares through affiliated entities.
• A new grant of 25,146 RSUs was awarded to the director on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director equity compensation.

Positives

• Director maintains significant alignment with shareholders through a large indirect ownership stake of over 13 million shares.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Future vesting of the 25,146 newly granted RSUs is contingent upon the director's continued service on the Board of Directors.

Future Outlook

The newly granted 25,146 RSUs are scheduled to vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date, provided the director remains in service.

Management Comments

• The reporting person disclaims beneficial ownership of the 13,021,324 indirectly held shares except to the extent of their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that this filing reflects standard director compensation practices within the medical device sector, where equity-based incentives are used to align board members with long-term corporate performance.

Comparison to Industry Standards

• The use of RSU vesting schedules is consistent with standard corporate governance practices for publicly traded medical technology companies.
• The director's significant indirect ownership stake is typical for venture-backed companies that have transitioned to public markets.

Related Party Transactions

• Disclosure of indirect ownership through EW Healthcare Partners Acquisition Fund and White Pine Medical, LLC.

Stakeholder Impact

• No material impact on shareholders or company operations; reflects standard director compensation.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership